Other substances

Silmitasertib

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
4
 AI-suggested references
2
 Clinical trials

Synonyms

CX-4945

 

Supporting references

Link Tested on Impact factor Notes Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule 		in silico 42.78 Apr/30/2020
Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Preprint 		human renal cortical epithelial cells

strong effect

 Apr/23/2020

AI-suggested references

Link Publication date
Mechanistic insights of key host proteins and potential repurposed inhibitors regulating SARS-CoV-2 pathway.
Dec/09/2021
Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics.
Jan/03/2022
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
Apr/04/2022
Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.
Jul/15/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04663737 Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 Active, not recruiting Phase 2 Dec/03/2020 Sep/30/2021
  • Alternative id - CX4945 AV01-IIT
  • Interventions - Drug: Silmitasertib|Drug: SOC
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Center for Advanced Research and Education, Gainesville, Georgia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 20
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) within the CX-4945 Treatment Group assessed by CTCAE v5.0|Clinical Recovery associated with COVID-19 within the CX-4945 Treatment Group|Anti-Viral Activity of CX-4945|Maximum Plasma Concentration [Cmax] of CX-4945|Clinical Benefit of CX-4945 i.e. All-Cause Mortality|Clinical Benefit of CX-4945 i.e. Number of Respiratory Failures|Clinical Benefit of CX-4945 i.e. Number of Hospitalized Days|Clinical Benefit of CX-4945 i.e. Changes in Pulse Oxygen Saturation|Clinical Benefit of CX-4945 i.e. Changes in Clinical Status|Clinical Benefit of CX-4945 i.e. Self-Reported Quality of Life|CX-4945 Inflammatory Marker Outcomes i.e. Plasma IL-6|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CRP|CX-4945 Inflammatory Marker Outcomes i.e. Plasma LDH|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CPK|CX-4945 Inflammatory Marker Outcomes i.e. Plasma Ferritin|CX-4945 Inflammatory Marker Outcomes i.e. Plasma D-Dimer
NCT04668209 Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) Recruiting Phase 2 Jan/01/2021 Mar/31/2022
  • Alternative id - CX4945-AV02-IIT
  • Interventions - Drug: Silmitasertib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Banner University Medical Center Phoenix, Phoenix, Arizona, United States|Banner University Medical Center Tucson, Tucson, Arizona, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]|To compare time to clinical recovery in CX-4945 treatment group evaluated from randomization through Day 28 as compared to the control arm.|To compare changes in clinical status of patients enrolled to CX-4945 treatment arm as compared to the control arm at Day 14 and Day 28.|To evaluate preliminary evidence of anti-viral activity of CX-4945 as compared to the control arm.|Number of Days Hospitalized|To evaluate changes in IL-6 level|To evaluate changes in CRP|To evaluate changes in LDH|To evaluate changes in CPK|To evaluate changes in Ferritin|To evaluate changes in D-dimer|Number of Days of Supplemental Oxygen Use|All-cause Mortality Status|Number of days of on-invasive ventilation/high flow oxygen|Number of days of invasive mechanical ventilation/ECMO|Number of patients returned to room air|Change in pulse oxygen saturation|Number of thrombosis events|Changes in EQ-D5-5L
Export (.csv)